Category: Pα+ - Psychedelic Alpha

Explore psychedelic drug development via our Q1'25 🎯 Bullseye Chart.

Read more about the article Behind the Scenes of the “Psychedelic Renaissance” at SXSW 2025

Behind the Scenes of the “Psychedelic Renaissance” at SXSW 2025

Post published:March 14, 2025
Post category:Analysis News Pα+

Read more about the article Inside the World’s Most Active Psychedelic Therapy Site: A Conversation with Sunstone Therapies

Inside the World’s Most Active Psychedelic Therapy Site: A Conversation with Sunstone Therapies

Post published:March 12, 2025
Post category:Interviews Pα+

Read more about the article Pα+ Psychedelic Bulletin #190: ‘Europe’s Most Feared Investor’ Teams Up with Musk Associate to Fund Lykos Therapeutics

Pα+ Psychedelic Bulletin #190: ‘Europe’s Most Feared Investor’ Teams Up with Musk Associate to Fund Lykos Therapeutics

Post published:March 6, 2025
Post category:Psychedelic Bulletin Pα+

Read more about the article Pα+ Psychedelic Bulletin #189: Psychedelic Philanthropists Weigh In on New Administration; Washington Lawmakers, Experts, Residents Debate Psychedelics Bills; Compass and GH Share Updates

Pα+ Psychedelic Bulletin #189: Psychedelic Philanthropists Weigh In on New Administration; Washington Lawmakers, Experts, Residents Debate Psychedelics Bills; Compass and GH Share Updates

Post published:February 28, 2025
Post category:Psychedelic Bulletin Pα+

Read more about the article Psychedelic Policy Push Continues: Over 60 Bills Introduced Across 22 States

Psychedelic Policy Push Continues: Over 60 Bills Introduced Across 22 States

Post published:February 27, 2025
Post category:Analysis News Pα+

Read more about the article January 2025 Psychedelic Patent Update: Lykos’ New Continuation Applications; Ambio Files on Ibogaine & Magnesium

January 2025 Psychedelic Patent Update: Lykos’ New Continuation Applications; Ambio Files on Ibogaine & Magnesium

Post published:February 25, 2025
Post category:Psychedelic Patent Analysis Pα+

Read more about the article MDMA for Active-Duty Troops: Aaron Wolfgang on DoD’s Unprecedented Study

MDMA for Active-Duty Troops: Aaron Wolfgang on DoD’s Unprecedented Study

Post published:February 19, 2025
Post category:Interviews Pα+

Read more about the article Pα+ Psychedelic Bulletin #188: Q4’24 Lobbying Update; Virginia Lawmakers Question Purpose, Precedent of Compass Bill; VA Loses Psychedelics Champion; GH Discusses Lack of Placebo Effect

Pα+ Psychedelic Bulletin #188: Q4’24 Lobbying Update; Virginia Lawmakers Question Purpose, Precedent of Compass Bill; VA Loses Psychedelics Champion; GH Discusses Lack of Placebo Effect

Post published:February 14, 2025
Post category:Psychedelic Bulletin Pα+

Read more about the article Ketamine on the Edge: Mindbloom’s At-Home Injections Spark Debate; UK Eyes Tougher Laws; DEA to Regulate Telehealth Prescribing; Spravato Sales Top $1bn

Ketamine on the Edge: Mindbloom’s At-Home Injections Spark Debate; UK Eyes Tougher Laws; DEA to Regulate Telehealth Prescribing; Spravato Sales Top $1bn

Post published:February 10, 2025
Post category:Analysis News Pα+

Read more about the article Pα+ Psychedelic Bulletin #187: NYT Article Reignites MDMA Rejection Blame Game; FDA “Wanted to Approve” MDMA, MindMed Exec Says; GH’s Data and RFK Jr. Confirmation Send Psychedelics Stocks Soaring

Pα+ Psychedelic Bulletin #187: NYT Article Reignites MDMA Rejection Blame Game; FDA “Wanted to Approve” MDMA, MindMed Exec Says; GH’s Data and RFK Jr. Confirmation Send Psychedelics Stocks Soaring

Post published:February 7, 2025
Post category:Psychedelic Bulletin Pα+

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.